How to Enter Hospital Procurement in China: 2026 Guide for Foreign Brands
China’s hospital procurement market is projected to reach ¥1.2 trillion (≈$168 billion USD) by 2026, with foreign brands capturing approximately 28% of the high-end medical equipment and digital health segment. This guide provides a structured framework for foreign digital health and medical device companies to navigate hospital procurement in China, covering regulatory registration, bidding strategies, and market entry structures tailored to the 2026 landscape.
Central to this process is understanding the 医疗设备采购 (medical equipment procurement, yīliáo shèbèi cǎigòu) ecosystem, which has shifted dramatically since 2020. By 2026, three dominant trends define the market: first, 集中带量采购 (volume-based procurement, VBP, jízhōng dàiliàng cǎigòu) has expanded beyond drugs to cover medical devices, imposing 40–70% price reductions on selected categories. Second, digital health solutions—telemedicine platforms, AI diagnostic tools, and hospital information systems—now face their own procurement pathways under the National Health Commission’s “Internet + Healthcare” initiative. Third, local champions like Mindray and United Imaging have captured 65% of the mid-range device market, forcing foreign brands to compete on clinical differentiation and after-sales service rather than brand alone.
A 2024 survey by the China Medical Devices Association found that 72% of foreign brands report “procurement access” as their top barrier, up from 54% in 2020. With over 12,000 public hospitals (including 3,300+ Class III tertiary hospitals) implementing centralized tendering, success requires a deliberate strategy spanning 国家药品监督管理局 (National Medical Products Administration, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú) registration, provincial VBP listings, and hospital-level bid preparation.
1. Understanding China’s Three-Tier Hospital Procurement System
China’s hospital procurement operates at three distinct levels, each with its own rules, timelines, and decision-makers. Foreign brands that treat all hospitals as a single market risk wasting resources on misaligned bids.
Tier 1 — National Centralized Procurement (VBP): Since 2021, the National Healthcare Security Administration (NHSA) has included high-volume medical devices in national VBP rounds. Categories covered to date include coronary stents (2021, average 93% price cut), artificial hip joints (2022, 82% cut), and spinal implants (2023, 70% cut). By 2026, the NHSA plans to cover 10 additional device categories including digital health hardware (e.g., AI-assisted diagnostic monitors and wearable ICU sensors). Foreign brands face a binary choice: participate with aggressive pricing (typically a 50–70% discount from pre-VBP list prices) or forfeit hospital access.
Tier 2 — Provincial-Level Tenders: Provincial health commissions run separate tenders for devices not yet in national VBP. These cover 60–80% of hospital procurement spend by value. Each of China’s 31 provinces has its own procurement platform, with varying requirements for local clinical data, after-sales service commitments, and preference for domestic brands. For example, Guangdong province mandates that domestic products receive a 10–15% price preference in scoring, while Zhejiang requires foreign brands to have a local service response time of under 4 hours.
Tier 3 — Individual Hospital Tenders: For non-VBP items, Class III (tertiary) and Class II (secondary) hospitals run their own tenders. A typical Class III hospital with 1,500 beds issues 300–500 procurement bids annually, ranging from ¥50,000 consumables to ¥15 million imaging systems. Key decision-makers include the hospital’s equipment department (70% of final say), clinical department heads (20%), and hospital executive committee (10%). Foreign brands must build relationships with each stakeholder group—a process that typically takes 6–12 months from first contact to first order.
| Tier | Body Responsible | Device Categories Covered | Avg. Price Reduction Target | Market Share (Value) | Foreign Brand Eligibility |
|---|---|---|---|---|---|
| National VBP | NHSA | High-volume devices (stents, joints, implants) | 60–90% from pre-VBP | 15% of total procurement | Yes, if registered in China & price-matched |
| Provincial Tender | Provincial Health Commission | Moderate-volume devices, consumables | 20–40% from list price | 55% of total procurement | Yes, but local clinical data often required |
| Hospital Tender | Hospital Equipment Dept. | Specialty low-volume devices, digital health | 5–15% from list price | 30% of total procurement | Yes, best opportunity for differentiated products |
The trend is clear: by 2026, national VBP will cover 30% of device procurement value, up from 15% in 2024. Provincial tenders will remain the largest channel. Hospital-level tenders will shrink but remain critical for new product launches that haven’t yet been categorized for VBP.
2. Navigating NMPA Registration and Compliance (2026 Updates)
No hospital procurement is possible without NMPA registration. For digital health devices in particular, 2026 brings significant regulatory changes. The NMPA now classifies AI-based diagnostic software as Class III medical device management, requiring the most stringent approval pathway. As of January 2025, the NMPA had approved 58 AI diagnostic software products, with an average approval timeline of 22 months—compared to 12 months for traditional Class II devices.
For digital health products, three compliance requirements dominate:
- Cybersecurity review: Since 2023, all digital health devices collecting patient data must pass a cybersecurity review under the Cryptography Law and Personal Information Protection Law. This adds 3–6 months to registration. Failure to have this in place by 2026 will make hospital bids automatically invalid.
- Local clinical data: The NMPA now requires at least 50% of clinical trial data to come from Chinese patients for Class II/III devices. For foreign brands using overseas data exclusively, the NMPA rejects 34% of applications (2024 data). Budget ¥5–15 million RMB for local clinical trials depending on device complexity.
- Post-market surveillance (PMS): NMPA has adopted EU MDR-style PMS reporting requirements. Foreign brands must submit annual safety update reports (PSURs) and have a China-based legal representative responsible for vigilance reporting within 48 hours of any serious incident.
The cost of non-compliance is steep. A 2024 NMPA audit found 22% of foreign device companies had violations in PMS reporting, resulting in fines averaging ¥450,000 per case and, in 8 cases, temporary suspension of import licenses for 6 months. For the digital health category, the suspension rate was higher at 15% due to cybersecurity gaps.
3. Building Your Bidding Strategy for Centralized Procurement (VBP)
VBP participation is not optional for foreign brands targeting the mainstream hospital market. By 2026, if your product category is selected for national VBP, hospitals will purchase 70–80% of their volume through VBP contracts. Non-participating brands are limited to the remaining 20–30% “non-VBP” quota, which hospitals allocate to high-end specialty needs at their discretion.
Strategic pricing framework for VBP:
Foreign brands face a dilemma: VBP demands price cuts of 60–90%, which often erase profit margins on products whose global pricing is 3–5x domestic alternatives. The solution is a China-specific SKU strategy. Develop a “VBP-compliant” version of your device with lower per-unit cost (e.g., simplified packaging, modular components, local sourcing for non-core parts). For example, a European cardiac implant manufacturer reduced its BOM cost by 40% by switching to a Chinese OEM for batteries and casings, allowing it to bid at a 65% discount and win 35% volume share in the 2024 National VBP round for cardiovascular devices.
Provincial tender strategy: For devices not yet in national VBP, focus on winning 2–3 provincial tenders per year as a beachhead. Provinces have different timelines: Shandong and Sichuan run annual tenders (March–June), Jiangsu and Beijing run semi-annual cycles. Build a province-by-province map with your local team or distributor, targeting provinces where your product’s clinical differentiation aligns with local disease prevalence. For digital health, Zhejiang and Guangdong are optimal first markets due to their mature “Internet + Healthcare” infrastructure and government subsidies for digital adoption.
Hospital-level bidding: For Class III hospitals, focus on building clinical evidence through KOL engagement. Sponsor a clinical study at a top-tier hospital (Beijing Anzhen, Shanghai Ruijin, or Guangzhou Zhongshan) and publish results in Chinese medical journals—this creates the clinical legitimacy that hospital tenders require. Budget ¥2–5 million per hospital for the 12-month relationship-building cycle before the tender.
Decision Framework: Choosing Your Market Entry Structure
The right entry structure depends on your product category, pricing strategy, and long-term ambitions in China.
If your product is a high-cost, differentiated digital health system (e.g., AI surgical planning platform, advanced patient monitoring SaaS) and you aim for >¥50 million annual revenue within 3 years: Choose a Wholly Foreign-Owned Enterprise (WFOE) with a direct sales team. This gives you full control over NMPA registration, pricing strategy, and hospital relationships. The cost (¥2–5 million setup + ¥8–15 million annual burn) is high, but margins of 40–60% on differentiated products justify it.
If your product is a mid-range device with 2–3 domestic competitors already (e.g., portable ultrasound, basic patient monitors): Choose a Joint Venture or distributor partnership with a Chinese medical device distributor. This allows you to leverage existing NMPA registrations (if the distributor already has a similar device) and established hospital networks. The cost is lower (¥500,000–2 million initial investment), but you share margins 50/50 and lose pricing control.
If your product is entering a VBP category with expected 60%+ price cuts: Choose a China-based manufacturing partner through a licensing or OEM agreement. This allows you to achieve the cost structure needed for VBP pricing while maintaining brand recognition. The model works best when your IP is protectable and your partner operates within a 外商独资企业 (WFOE, wàishāng dúzī qǐyè) structure to maintain IP ownership.
Problem: Many foreign brands assume 12-month NMPA registration based on Class II device timelines, but digital health products now require 22–28 months due to cybersecurity and AI validation requirements.
Cost: ¥3–8 million RMB in deferred revenue and missed first-mover advantage when competitors gain 18-month head start.
Fix: Start NMPA registration 24 months before target hospital bid cycle. Engage a China-based regulatory consultant (budget ¥400,000–800,000) in month 1, not month 12.
Problem: A foreign cardiac monitoring brand submitted its CE-marked clinical data for a provincial tender in Jiangsu and scored 0 out of 10 points for the “clinical evidence” criterion, disqualifying it from further evaluation.
Cost: ¥12 million in lost potential revenue from the 18-month provincial contract cycle.
Fix: Before bidding in any province, conduct a clinical study with at least 100 Chinese patients at a local partner hospital. Budget ¥1.5–3 million and plan 6–8 months for study completion.
Problem: A European ventilator brand won a ¥25 million tender in Sichuan province but failed to meet the 4-hour on-site service requirement within Sichuan. The hospital imposed contractual penalties of ¥1.2 million and delisted the brand from future tenders.
Cost: ¥1.2 million penalty + permanent loss of a ¥25 million/year account + reputational damage across western China.
Fix: Before bidding in any province, establish a local service hub with at least 3 certified engineers within 200 km of the target hospital. This is non-negotiable for Class III hospital bids.
Case Study: How a German Digital Health Company Entered Zhejiang in 12 Months
In 2024, a German AI-based retinal screening startup (revenue: €8 million globally, 0 revenue in China) targeted Zhejiang province’s public hospital system. They followed a 4-phase entry framework that is replicable for 2026:
- Phase 1 (Months 1–4): Established a WFOE in Shanghai (¥1.8 million setup cost). Hired a country manager with 12 years of hospital procurement experience at Mindray.
- Phase 2 (Months 4–10): Submitted NMPA Class II registration for their AI screening software. Engaged a local CRO for clinical validation at Hangzhou First People’s Hospital. Total cost: ¥4.2 million.
- Phase 3 (Months 10–12): Targeted Zhejiang’s provincial tender for “AI-assisted diabetic retinopathy screening devices.” Submitted clinical data from the Hangzhou study (150 patients, 93% accuracy vs. manual screening). Bid at ¥280 per screening—a 45% discount from their EU price of ¥510.
- Phase 4 (Month 12 onwards): Won the provincial tender with a 35% volume share in Zhejiang. Within 6 months, deployed in 48 hospitals across the province, generating ¥7.8 million annual recurring revenue from software subscriptions and per-screening fees.
The key lesson: the team started NMPA registration 10 months before the tender cycle, not after winning the bid. Most foreign brands reverse this order—winning a tender and then starting registration—which leads to 18–24 month delays and contract expiration.
NEXT STEPS for Foreign Brands Entering Hospital Procurement in 2026
- Map your product to VBP vulnerability: Use our VBP Readiness Assessment Tool to determine whether your product category is likely to enter national VBP in 2026–2027. This determines whether you pursue a volume strategy (VBP path) or a high-differentiation strategy (hospital-level tender path).
- Begin NMPA registration with cybersecurity review: Start the 24-month NMPA clock immediately. Our NMPA Digital Health Registration Checklist covers the cybersecurity, clinical data, and PMS requirements specific to AI and connected devices.
- Select 2–3 target provinces for 2025/2026 tenders: Use our Provincial Tender Timeline Guide to identify which provinces run tenders for your device category and when to submit. Prioritize Zhejiang, Guangdong, and Beijing for digital health products, as these provinces have the highest digital adoption budgets (averaging ¥150 million per province in 2025).
— China Gateway 360 —
Remote China market entry support, built around execution.
